Syngene International Future Growth

Future criteria checks 2/6

Syngene International is forecast to grow earnings and revenue by 14.4% and 13.2% per annum respectively. EPS is expected to grow by 14.1% per annum. Return on equity is forecast to be 13.3% in 3 years.

Key information

14.4%

Earnings growth rate

14.1%

EPS growth rate

Life Sciences earnings growth	24.8%
Revenue growth rate	13.2%
Future return on equity	13.3%
Analyst coverage	Good
Last updated	26 Apr 2024

Recent future growth updates

Syngene International Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jan 23

Recent updates

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Mar 28

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Apr 28

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Apr 06

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Jan 04

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Dec 08

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Aug 28

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Aug 10

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

May 10

Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?

Feb 02

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Nov 26

Here's Why Syngene International (NSE:SYNGENE) Can Manage Its Debt Responsibly

Sep 21

Here's Why I Think Syngene International (NSE:SYNGENE) Is An Interesting Stock

Aug 06

The CEO Of Syngene International Limited (NSE:SYNGENE) Might See A Pay Rise On The Horizon

Jul 14

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Jun 09

We Think Syngene International (NSE:SYNGENE) Can Stay On Top Of Its Debt

Feb 18

Syngene International Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Jan 23

Earnings and Revenue Growth Forecasts

NSEI:SYNGENE - Analysts future estimates and past financials data (INR Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
3/31/2027	51,103	7,552	4,270	12,137	5
3/31/2026	46,323	7,223	3,441	12,233	8
3/31/2025	38,243	5,674	1,644	9,458	6
3/31/2024	34,886	5,100	5,313	10,421	N/A
12/31/2023	35,661	5,002	N/A	N/A	N/A
9/30/2023	34,985	4,984	4,706	10,290	N/A
6/30/2023	33,565	4,839	N/A	N/A	N/A
3/31/2023	31,929	4,644	3,052	8,235	N/A
12/31/2022	29,566	4,334	N/A	N/A	N/A
9/30/2022	28,121	4,277	1,083	5,898	N/A
6/30/2022	26,542	3,924	N/A	N/A	N/A
3/31/2022	26,042	3,958	1,051	5,806	N/A
12/31/2021	25,047	4,086	N/A	N/A	N/A
9/30/2021	24,478	4,068	2,102	6,566	N/A
6/30/2021	23,572	4,242	N/A	N/A	N/A
3/31/2021	21,843	4,049	2,547	7,012	N/A
12/31/2020	21,330	3,645	N/A	N/A	N/A
9/30/2020	20,676	3,541	1,217	6,318	N/A
6/30/2020	20,126	3,981	N/A	N/A	N/A
3/31/2020	20,119	4,121	340	6,771	N/A
12/31/2019	19,385	3,920	N/A	N/A	N/A
9/30/2019	18,865	3,872	1,257	7,549	N/A
6/30/2019	18,405	3,374	N/A	N/A	N/A
3/31/2019	18,256	3,316	471	6,304	N/A
12/31/2018	17,008	3,160	N/A	N/A	N/A
9/30/2018	16,214	3,110	N/A	N/A	N/A
6/30/2018	15,380	3,096	N/A	N/A	N/A
3/31/2018	14,231	3,054	825	4,462	N/A
12/31/2017	13,053	2,993	N/A	N/A	N/A
9/30/2017	12,497	2,917	N/A	N/A	N/A
6/30/2017	12,175	2,895	N/A	N/A	N/A
3/31/2017	12,009	2,873	N/A	3,977	N/A
12/31/2016	12,411	2,682	N/A	N/A	N/A
9/30/2016	11,894	2,606	N/A	N/A	N/A
6/30/2016	11,479	2,344	N/A	N/A	N/A
3/31/2016	11,070	2,408	N/A	3,081	N/A
12/31/2015	10,235	2,103	N/A	N/A	N/A
9/30/2015	9,713	1,964	N/A	N/A	N/A
6/30/2015	9,017	1,843	N/A	N/A	N/A
3/31/2015	8,599	1,750	N/A	185	N/A
3/31/2014	6,995	1,339	N/A	2,995	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: SYNGENE's forecast earnings growth (14.4% per year) is above the savings rate (6.7%).

Earnings vs Market: SYNGENE's earnings (14.4% per year) are forecast to grow slower than the Indian market (17.3% per year).

High Growth Earnings: SYNGENE's earnings are forecast to grow, but not significantly.

Revenue vs Market: SYNGENE's revenue (13.2% per year) is forecast to grow faster than the Indian market (9.9% per year).

High Growth Revenue: SYNGENE's revenue (13.2% per year) is forecast to grow slower than 20% per year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: SYNGENE's Return on Equity is forecast to be low in 3 years time (13.3%).

Syngene International Future Growth

Future criteria checks 2/6

Key information

Recent future growth updates

Price target increased by 8.9% to ₹808

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Syngene International Limited Provides Earnings Guidance for the Year 2022

Price target increased to ₹673

Syngene International Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next

Recent updates

Dividend of ₹1.25 announced

Syngene International Limited, Annual General Meeting, Jul 24, 2024

Full year 2024 earnings: EPS exceeds analyst expectations while revenues lag behind

Syngene International Limited Recommends Final Dividend for the Financial Year 2024

Syngene International Limited to Report Q4, 2024 Results on Apr 24, 2024

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Head of IT recently sold ₹1.5m worth of stock

Do Syngene International's (NSE:SYNGENE) Earnings Warrant Your Attention?

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Syngene International Limited Appoints Mr. Sibaji Biswas as Additional Director Designated as Executive Director, Effective on April 01, 2024

Earnings Not Telling The Story For Syngene International Limited (NSE:SYNGENE)

Insider recently sold ₹9.9m worth of stock

Syngene International Limited to Report Q3, 2024 Results on Jan 25, 2024

Head of Investor Relations recently sold ₹1.7m worth of stock

Head of Investor Relations recently sold ₹1.8m worth of stock

Is Syngene International (NSE:SYNGENE) A Risky Investment?

Insider recently sold ₹7.1m worth of stock

Syngene International Limited Announces Resignation of Mahesh Bhalgat as Chief Operating Officer, Effective January 31, 2024

Is Now The Time To Put Syngene International (NSE:SYNGENE) On Your Watchlist?

Syngene International Limited Announces Resignation of Carl Decicco as Non-Executive Director

Second quarter 2024 earnings released: EPS: ₹2.90 (vs ₹2.55 in 2Q 2023)

Syngene International Limited Announces Retirement of Joydeep Kant as Sr. Vice President - Development Services, Effective October 31, 2023

Syngene International Limited to Report Q2, 2024 Results on Oct 17, 2023

Chief Financial Officer recently sold ₹57m worth of stock

Insider recently sold ₹2.4m worth of stock

Syngene International (NSE:SYNGENE) Seems To Use Debt Rather Sparingly

Price target increased by 8.9% to ₹808

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Upcoming dividend of ₹1.25 per share at 0.1% yield

Insider recently sold ₹2.3m worth of stock

MD, CEO & Executive Director recently sold ₹166m worth of stock

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Safely

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Here's Why We Think Syngene International (NSE:SYNGENE) Is Well Worth Watching

Insider recently sold ₹2.1m worth of stock

Insider recently sold ₹4.6m worth of stock

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.9m worth of stock

Syngene International Limited Confirms Financial Guidance for Fiscal 2023

Third quarter 2023 earnings released: EPS: ₹2.74 (vs ₹2.57 in 3Q 2022)

Does Syngene International (NSE:SYNGENE) Deserve A Spot On Your Watchlist?

Insider recently sold ₹1.1m worth of stock

Insider recently sold ₹2.4m worth of stock

Syngene International (NSE:SYNGENE) Has A Pretty Healthy Balance Sheet

Insider recently sold ₹1.0m worth of stock

Insider recently sold ₹7.8m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹1.2m worth of stock

Insider recently sold ₹4.3m worth of stock

Syngene International Limited Provides Earnings Guidance for the Year 2022

Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Insider recently sold ₹1.1m worth of stock

MD, CEO & Executive Director recently sold ₹20m worth of stock

Is Syngene International (NSE:SYNGENE) Using Too Much Debt?

Chief Human Resources Officer recently sold ₹13m worth of stock

Syngene International Limited (NSE:SYNGENE) Shares Could Be 22% Above Their Intrinsic Value Estimate

Insider recently sold ₹4.0m worth of stock

Syngene International Limited Approves the Additional Special Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q3, 2023 Results on Jan 23, 2023

Upcoming dividend of ₹1.00 per share

Syngene International Limited Recommends Special Additional Dividend for the Financial Year Ended March 31, 2022

These 4 Measures Indicate That Syngene International (NSE:SYNGENE) Is Using Debt Reasonably Well

Insider recently sold ₹1.7m worth of stock

Syngene International Limited Recommends Final Dividend for the Financial Year Ended March 31, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Syngene International Limited to Report Q4, 2022 Results on Apr 27, 2022

Syngene International Limited Appoints Carl Decicco as Additional Director Non-Executive Non-Independent of the Company

Does Syngene International (NSE:SYNGENE) Have A Healthy Balance Sheet?

Third quarter 2022 earnings: EPS and revenues miss analyst expectations